{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:39:26Z","timestamp":1792791566291,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00dcB\u0130TAK","doi-asserted-by":"publisher","award":["123Z180"],"award-info":[{"award-number":["123Z180"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.neuropharm.2026.111161","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:41:12Z","timestamp":1787848872000},"page":"111161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intraperitoneal administration of adenosine A2A receptor antagonist reduces neuroinflammatory and antioxidant responses in GM2 gangliosidosis mouse model"],"prefix":"10.1016","volume":"301","author":[{"given":"Nurselin","family":"Ates","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0243-5011","authenticated-orcid":false,"given":"Volkan","family":"Seyrantepe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2026.111161_bib1","article-title":"Adenosine A2A receptor as a dual-acting molecular switch: glial morphological changes and neurovascular tissue remodeling in neuroinflammation and neurodegeneration","volume":"100","author":"Abd El-Moaty","year":"2026","journal-title":"Tissue Cell"},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111161_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-022-01207-5","article-title":"Neurodegeneration and neuroinflammation in parkinson's disease: a self-sustained loop","volume":"22","author":"Arena","year":"2022","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111161_bib3","doi-asserted-by":"crossref","DOI":"10.1007\/s11033-025-10380-y","article-title":"Redox imbalance is associated with neurodegeneration in a murine model of tay-sachs disease","volume":"52","author":"Bas\u0131rl\u0131","year":"2025","journal-title":"Mol. Biol. Rep."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111161_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2018.05.014","article-title":"A combination of ontogeny and CNS environment establishes microglial identity","volume":"98","author":"Bennett","year":"2018","journal-title":"Neuron"},{"issue":"OCT","key":"10.1016\/j.neuropharm.2026.111161_bib5","article-title":"Neuroinflammatory paradigms in lysosomal storage diseases","volume":"9","author":"Bosch","year":"2015","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111161_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-022-02584-x","article-title":"Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer's and Parkinson's diseases","volume":"19","author":"Boyd","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111161_bib7","article-title":"Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting activation of nuclear factor-\u03baB and nuclear factor of activated T cells","volume":"299","author":"Bradley","year":"2001","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111161_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/nn.3599","article-title":"Identification of a unique TGF-\u03b2-dependent molecular and functional signature in microglia","volume":"17","author":"Butovsky","year":"2014","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111161_bib9","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson's disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic signaling"},{"issue":"26","key":"10.1016\/j.neuropharm.2026.111161_bib10","doi-asserted-by":"crossref","DOI":"10.2174\/1381612825666190712181955","article-title":"Adenosine receptors in modulation of central nervous system disorders","volume":"25","author":"Choudhury","year":"2019","journal-title":"Curr. Pharm. Des."},{"issue":"APR","key":"10.1016\/j.neuropharm.2026.111161_bib11","article-title":"Role of adenosine in oligodendrocyte precursor maturation","volume":"9","author":"Coppi","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2026.111161_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2013.05.035","article-title":"Adenosine A2A receptors inhibit delayed rectifier potassium currents and cell differentiation in primary purified oligodendrocyte cultures","volume":"73","author":"Coppi","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2026.111161_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2021.113543","article-title":"Hyperthermia-induced seizures during neonatal period alter the functionality of A1 and A2A receptors in the cerebellum and evoke fine motor impairment and gait disturbances in adult rats","volume":"240","author":"Crespo","year":"2021","journal-title":"Physiol. Behav."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111161_bib14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jnc.13724","article-title":"How does adenosine control neuronal dysfunction and neurodegeneration?","volume":"139","author":"Cunha","year":"2016","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111161_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-020-01947-6","article-title":"GM2 ganglioside accumulation causes neuroinflammation and behavioral alterations in a mouse model of early onset tay-sachs disease","volume":"17","author":"Demir","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2026.111161_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104338","article-title":"Adenosine A2A receptor as a potential therapeutic target in neuropsychiatric disorders","volume":"147","author":"Domenici","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2026.111161_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fnmol.2018.00235","article-title":"Beneficial effect of a selective adenosine A2A receptor antagonist in the APPswe\/PS1dE9 mouse model of Alzheimer's disease","volume":"11","author":"Faivre","year":"2018","journal-title":"Front. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111161_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.tins.2023.11.003","article-title":"White matter injury across neurodegenerative disease","volume":"47","author":"Festa","year":"2024","journal-title":"Trends Neurosci."},{"issue":"14","key":"10.1016\/j.neuropharm.2026.111161_bib19","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/mds.21440","article-title":"Adenosine A2A receptors, dopamine D2 receptors and their interactions in parkinson's disease","volume":"22","author":"Fuxe","year":"2007","journal-title":"Mov. Disord.: Off. J. Mov. Disord. Soc."},{"key":"10.1016\/j.neuropharm.2026.111161_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.irn.2023.08.002","article-title":"Adenosine A2A receptor and glia","volume":"170","author":"Gao","year":"2023","journal-title":"Int. Rev. Neurobiol."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111161_bib21","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1093\/brain\/awae113","article-title":"Neuronal A2A receptor exacerbates synapse loss and memory deficits in APP\/PS1 mice","volume":"147","author":"Gomez-Murcia","year":"2024","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111161_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/ana.24867","article-title":"Caffeine alleviates progressive motor deficits in a transgenic mouse model of spinocerebellar ataxia","volume":"81","author":"Gon\u00e7alves","year":"2017","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2026.111161_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2014.03.004","article-title":"Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease","volume":"67","author":"Gyoneva","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2026.111161_bib24","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3389\/fnana.2011.00048","article-title":"Identification of a specific assembly of the G protein golf as a critical and regulated module of dopamine- and adenosine-activated cAMP pathways in the striatum","volume":"5","author":"Herv\u00e9","year":"2011","journal-title":"Front. Neuroanat."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111161_bib25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11302-012-9298-3","article-title":"Constitutive activity of the A2A adenosine receptor and compartmentalized cyclic AMP signaling fine-tune noradrenaline release","volume":"8","author":"Ibrisimovic","year":"2012","journal-title":"Purinergic Signal."},{"issue":"26","key":"10.1016\/j.neuropharm.2026.111161_bib26","doi-asserted-by":"crossref","DOI":"10.2174\/1381612825666190716112319","article-title":"Therapeutic potential of agonists and antagonists of A1, A2a, A2b, and A3 adenosine receptors","volume":"25","author":"Jamwal","year":"2019","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111161_bib27","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awg089","article-title":"Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis","volume":"126","author":"Jeyakumar","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.neuropharm.2026.111161_bib28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3389\/fphar.2018.00133","article-title":"Adenosine A2A receptors control glutamatergic synaptic plasticity in fast spiking interneurons of the prefrontal cortex","volume":"9","author":"Kerkhofs","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2026.111161_bib29","doi-asserted-by":"crossref","DOI":"10.2147\/JIR.S287346","article-title":"Adenosine A2a receptor agonist polydeoxyribonucleotide alleviates interstitial cystitis-induced voiding dysfunction by suppressing inflammation and apoptosis in rats","volume":"14","author":"Ko","year":"2021","journal-title":"J. Inflamm. Res."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.111161_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/glia.23641","article-title":"Hexb enzyme deficiency leads to lysosomal abnormalities in radial glia and microglia in zebrafish brain development","volume":"67","author":"Kuil","year":"2019","journal-title":"Glia"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111161_bib31","article-title":"Chemokine CCL2 and its receptor CCR2 in regulation of cognitive functions and in development of aging diseases","volume":"12","author":"Kuznik","year":"2022","journal-title":"Biol. Bullet. Rev."},{"issue":"28","key":"10.1016\/j.neuropharm.2026.111161_bib32","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.2174\/0929867329666220218094501","article-title":"A2A; adenosine receptor antagonists and their potential in neurological disorders","volume":"29","author":"Lambertucci","year":"2022","journal-title":"Curr. Med. Chem."},{"issue":"17","key":"10.1016\/j.neuropharm.2026.111161_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176213","article-title":"Gm2 gangliosidoses: clinical features, pathophysiological aspects, and current therapies","volume":"21","author":"Leal","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2026.111161_bib34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nbd.2015.03.030","article-title":"Inactivation of adenosine A2A receptors reverses working memory deficits at early stages of huntington's disease models","volume":"79","author":"Li","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2026.111161_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.neuropharm.2026.111161_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.666710","article-title":"Astrocytes and adenosine A2A receptors: active players in Alzheimer's disease","volume":"15","author":"Lopes","year":"2021","journal-title":"Front. Neurosci."},{"issue":"9","key":"10.1016\/j.neuropharm.2026.111161_bib37","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/glia.24384","article-title":"Astrocytic A2A receptors silencing negatively impacts hippocampal synaptic plasticity and memory of adult mice","volume":"71","author":"Madeira","year":"2023","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111161_bib38","doi-asserted-by":"crossref","DOI":"10.1093\/mutage\/gez046","article-title":"Functions of the major abasic endonuclease (APE1) in cell viability and genotoxin resistance","volume":"35","author":"McNeill","year":"2020","journal-title":"Mutagenesis"},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111161_bib39","doi-asserted-by":"crossref","DOI":"10.1089\/ars.2012.5149","article-title":"Reactive oxygen species in inflammation and tissue injury","volume":"20","author":"Mittal","year":"2014","journal-title":"Antioxidants Redox Signal."},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111161_bib40","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s12035-020-02275-9","article-title":"Motor deficits coupled to cerebellar and striatal alterations in Ube3a m\u2212\/p+ mice modelling angelman syndrome are attenuated by adenosine A2A receptor blockade","volume":"58","author":"Moreira-de-S\u00e1","year":"2021","journal-title":"Mol. Neurobiol."},{"issue":"7","key":"10.1016\/j.neuropharm.2026.111161_bib41","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.3390\/molecules27072366","article-title":"The pharmacological potential of adenosine A2A receptor antagonists for treating Parkinson's disease","volume":"27","author":"Mori","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2026.111161_bib42","first-page":"304","article-title":"Blocking striatal adenosine A2A receptors: A new strategy for basal ganglia disorders","volume":"1","author":"Muller","year":"2007","journal-title":"Front. CNS Drug Discov."},{"key":"10.1016\/j.neuropharm.2026.111161_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2018.07.014","article-title":"Inhibition of astrocytic adenosine receptor A2A attenuates microglial activation in a mouse model of Sandhoff disease","volume":"118","author":"Ogawa","year":"2018","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111161_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/antiox12020517","article-title":"Oxidative stress and antioxidants in neurodegenerative disorders","volume":"12","author":"Olufunmilayo","year":"2023","journal-title":"Antioxidants"},{"issue":"1\u20102","key":"10.1016\/j.neuropharm.2026.111161_bib45","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ddr.1137","article-title":"Dual actions of A2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes","volume":"52","author":"Ongini","year":"2001","journal-title":"Drug Dev. Res."},{"issue":"12","key":"10.1016\/j.neuropharm.2026.111161_bib46","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1002\/glia.23688","article-title":"A2AR\u2010induced transcriptional deregulation in astrocytes: an in vitro study","volume":"67","author":"Paiva","year":"2019","journal-title":"Glia"},{"issue":"14","key":"10.1016\/j.neuropharm.2026.111161_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22147685","article-title":"Adenosine and inflammation: here, there, and everywhere","volume":"22","author":"Pasquini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111161_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/5.1.1","article-title":"Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases","volume":"5","author":"Phaneuf","year":"1996","journal-title":"Hum. Mol. Genet."},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2026.111161_bib49","article-title":"Functions, dysfunctions, and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease","volume":"81","author":"Popoli","year":"2007","journal-title":"Prog. Neurobiol."},{"issue":"13","key":"10.1016\/j.neuropharm.2026.111161_bib50","article-title":"Inhibitory feedback control of NF-?B signaling in health and disease","volume":"478","author":"Prescott","year":"2021","journal-title":"Biochem. J."},{"issue":"11","key":"10.1016\/j.neuropharm.2026.111161_bib51","first-page":"2979","article-title":"Adenosine receptors in neuroinflammation and neurodegeneration","volume":"11","author":"Salmaso","year":"2023","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.neuropharm.2026.111161_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay\u2013Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism","volume":"11","author":"Sango","year":"1995","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111161_bib53","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","article-title":"Adenosine A2A receptors and basal ganglia physiology","volume":"83","author":"Schiffmann","year":"2007","journal-title":"Prog. Neurobiol."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111161_bib54","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0301-0082(95)00035-6","article-title":"Adenosine A2 receptor-mediated excitatory actions on the nervous system","volume":"48","author":"Sebastiao","year":"1996","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2026.111161_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2017.09.012","article-title":"Murine Sialidase Neu3 facilitates GM2 degradation and bypass in a mouse model of Tay-Sachs disease","volume":"299","author":"Seyrantepe","year":"2018","journal-title":"Exp. Neurol."},{"issue":"26","key":"10.1016\/j.neuropharm.2026.111161_bib56","doi-asserted-by":"crossref","DOI":"10.2174\/1381612825666190716145206","article-title":"Role and function of adenosine and its receptors in inflammation, neuroinflammation, IBS, autoimmune inflammatory disorders, rheumatoid arthritis, and psoriasis","volume":"25","author":"Shakya","year":"2019","journal-title":"Curr. Pharm. Des."},{"issue":"8","key":"10.1016\/j.neuropharm.2026.111161_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/antiox9080743","article-title":"ROS generation in microglia: understanding oxidative stress and inflammation in neurodegenerative disease","volume":"9","author":"Simpson","year":"2020","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.neuropharm.2026.111161_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22040676","article-title":"Adenosine A1 and A2A receptors in the brain: current research and their role in neurodegeneration","volume":"22","author":"Stockwell","year":"2017","journal-title":"Molecules"},{"issue":"18","key":"10.1016\/j.neuropharm.2026.111161_bib59","doi-asserted-by":"crossref","DOI":"10.1046\/j.1432-1033.2002.03157.x","article-title":"Inhibition of the NF-\u03baB transcriptional activity by protein kinase A","volume":"269","author":"Takahashi","year":"2002","journal-title":"Eur. J. Biochem."},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111161_bib60","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.13419","article-title":"The impact of neuroinflammation on neuronal integrity","volume":"327","author":"Tastan","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.neuropharm.2026.111161_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136195","article-title":"The GM2 gangliosidoses: unlocking the mysteries of pathogenesis and treatment","volume":"764","author":"Toro","year":"2021","journal-title":"Neurosci. Lett."},{"issue":"5","key":"10.1016\/j.neuropharm.2026.111161_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/j.1742-4658.2006.05126.x","article-title":"The enzyme-binding region of human GM2-activator protein","volume":"273","author":"Wendeler","year":"2006","journal-title":"FEBS J."},{"issue":"3","key":"10.1016\/j.neuropharm.2026.111161_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2004.10.007","article-title":"Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease","volume":"105","author":"Xu","year":"2005","journal-title":"Pharmacol. Ther."},{"issue":"21","key":"10.1016\/j.neuropharm.2026.111161_bib64","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.91.21.9975","article-title":"Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease","volume":"91","author":"Yamanaka","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.neuropharm.2026.111161_bib65","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0092-22.2022","article-title":"P2X7 receptor and purinergic signaling: orchestrating mitochondrial dysfunction in neurodegenerative diseases","volume":"9","author":"Zelentsova","year":"2022","journal-title":"eNeuro"},{"issue":"1","key":"10.1016\/j.neuropharm.2026.111161_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-023-01486-5","article-title":"Role of neuroinflammation in neurodegeneration development","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390826003369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:57:36Z","timestamp":1792789056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390826003369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":66,"alternative-id":["S0028390826003369"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111161","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal administration of adenosine A2A receptor antagonist reduces neuroinflammatory and antioxidant responses in GM2 gangliosidosis mouse model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2026.111161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111161"}}